Binds Specifically-identified Amino Acid Sequence Patents (Class 530/387.9)
  • Patent number: 10227411
    Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: March 12, 2019
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Seung Chu, Dilki Wickramarachichi, John Desjarlais
  • Patent number: 9869683
    Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: January 16, 2018
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
  • Patent number: 9829494
    Abstract: The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used as for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: November 28, 2017
    Assignee: ADRENOMED AG
    Inventors: Andreas Bergmann, Joachim Struck, Nils G. Morgenthaler
  • Patent number: 9758591
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 12, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
  • Patent number: 9663567
    Abstract: The invention relates to monoclonal antibodies (mAbs) that bind to serotransferrin (TF), hybridoma lines that secrete these antibodies or fragments thereof, and the use of these antibodies to detect TF antigens. Methods and uses for detecting prostate cancer, as well as methods and uses for distinguishing early and late stage prostate cancer are encompassed.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 30, 2017
    Assignee: ALPER BIOTECH LLC
    Inventor: Özge Alper
  • Patent number: 9655899
    Abstract: The instant invention relates to methods for the treatment of WEE1 kinase associated cancer by administering a WEE1 inhibitor, wherein the WEE1 inhibitor is WEE1-1 or a pharmaceutically acceptable salt thereof, or WEE1-2 or a pharmaceutically acceptable salt thereof. In another embodiment, the invention relates to a method for treating a WEE1 kinase associated cancer patient, comprising administering a WEE1 inhibitor, wherein the cancer cells of said patient to be treated are characterized by low expression levels of PKMYT1.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: May 23, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Stuart Denham Shumway
  • Patent number: 9512231
    Abstract: The disclosure relates to a polypeptide comprising at least four domains specifically binding to a certain MHC peptide complex, the domains separated by linker amino acid sequences, thereby providing each domain with the capability to bind a separate MHC peptide complex, to a nucleic acid encoding for such a polypeptide, to a vector comprising such a nucleic acid, to a host cell for expression of such a polypeptide, to a pharmaceutical composition comprising such a polypeptide, and to a kit of parts comprising at least two polypeptides according to the disclosure.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 6, 2016
    Assignee: APO-T B.V.
    Inventors: Ralph Alexander Willemsen, Maria Johanna J. E. Van Driel
  • Patent number: 9365647
    Abstract: The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (?) and gamma (?) secretases and amyloid beta peptide (A?), and also relates to a method of reducing A? shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: June 14, 2016
    Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Stefan Franz Thomas Weiss, Katarina Jovanovic, Danielle Gonsavles, Bianca Da Costa Dias, Stefan Knackmuss, Uwe Reusch, Melvyn Little, Marc Saul Weinberg
  • Patent number: 9347957
    Abstract: The present invention provides a reagent for assaying D-dimer which includes carriers sensitized to first and second monoclonal antibodies which react with D-dimer, but have different reactivity to D-dimer in which the first monoclonal antibody reacts with high- and low-molecular fractions of D-dimer, the second monoclonal antibody reacts with the high-molecular fraction, but reactivity of the second monoclonal antibody with the low-molecular fraction is different from that of the first monoclonal antibody and a kit of reagent for assaying D-dimer.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: May 24, 2016
    Assignee: SYSMEX CORPORATION
    Inventors: Keisuke Nagai, Kazuaki Yamashita, Susumu Hoshiko, Takeshi Suzuki
  • Patent number: 9285371
    Abstract: Provided is a method of screening a target-specific antibody for an antigen that undergoes structural change in a particular physiological condition.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: March 15, 2016
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Min-Kyung Kim, Jae-Il Lee
  • Patent number: 9201068
    Abstract: The present invention is directed to a method and apparatus that satisfies the need for a bioelectronic tongue for food allergy detection. The method of detecting concentration of food allergen incorporates antibodies into an electronic tongue to create a bioelectronic tongue. Additionally the method uses impedance, capacitance, and/or other related electrochemical methods for detecting analyte in complex media. Furthermore the method additionally includes methods to subtract out non-specific interactions. The method also subtracts non-specific interactions. The device/apparatus is a Bioelectronic Tongue for detecting allergen in diluted food samples. The device includes: a sensor array; an impedance or capacitance analyzer; a preprocessor; a feature extractor; a pattern recognizer; and an output device indicating an allergen concentration.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: December 1, 2015
    Assignee: CLARKSON UNIVERSITY
    Inventors: Ian Ivar Suni, Yin Huang, Stephanie Ann Caswell Schuckers
  • Patent number: 9175073
    Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 3, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Keiko Yamaguchi, Toshio Imai, Kenzo Muramoto
  • Patent number: 9150658
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: October 6, 2015
    Assignee: GENMAB A/S
    Inventors: Sandra Verploegen, David P. E. Satijn, Rene Hoet, Paul Parren, Jan Van De Winkel, Vibeke Miller Breinholt, Eva Ehrnrooth, Ole Baadsgaard, Tom Vink, Willem Karel Bleeker, Mischa Houtkamp, Maroeska Oudshoorn, Rob N. De Jong
  • Patent number: 9073998
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: July 7, 2015
    Assignee: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • Publication number: 20150147330
    Abstract: Described herein is the identification of a panel of high affinity monoclonal antibodies that bind GPC3. The disclosed antibodies recognize native GPC3 on the surface of cancer cells, as well as soluble GPC3. The highest affinity antibody (YP7) was further characterized and shown to be highly sensitive in that it was capable of detecting cancer cells with low expression of GPC3. YP7 also exhibited significant HCC tumor growth inhibition in vivo. Immunotoxins comprising the antibodies disclosed herein fused to PE38 exhibited very high binding affinity for GPC3-expressing cells and significantly inhibited GPC3-expressing cancer cell growth. Thus, the high-affinity monoclonal antibodies disclosed herein can be used for the diagnosis and treatment of GPC3-expressing cancers.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 28, 2015
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventors: Mitchell Ho, Yen T. Phung, Wei Gao, Yifan Zhang
  • Publication number: 20150147274
    Abstract: Antibodies which are antagonists of the human HGF receptor (MET), wherein the antibodies specifically bind to amino acid residues 568-741 of human MET (SEQ ID No: 1) with high affinity.
    Type: Application
    Filed: November 30, 2012
    Publication date: May 28, 2015
    Inventors: Danielle Marie Di Cara, John McCafferty, Ermanno Gherardi, Anthony Richard Pope
  • Publication number: 20150147316
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 28, 2015
    Applicant: SEATTLE GENETICS, INC.
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • Publication number: 20150147333
    Abstract: Provided herein are anti-RSPO antibodies, in particular anti-RSPO2 antibodies and/or anti-RSPO3 antibodies, and methods of using the same.
    Type: Application
    Filed: October 17, 2014
    Publication date: May 28, 2015
    Applicant: GENENTECH, INC.
    Inventors: Elaine Storm, Frederic J. de Sauvage, Jeremy M. Murray, Cameron L. Noland, Yan Wu, Christine Tan, Jo-Anne Hongo, Yongmei Chen
  • Publication number: 20150147784
    Abstract: Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.
    Type: Application
    Filed: December 1, 2014
    Publication date: May 28, 2015
    Inventors: Xuguang Li, Runtao He, Gary Van Domselaar
  • Publication number: 20150147329
    Abstract: The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.
    Type: Application
    Filed: July 25, 2014
    Publication date: May 28, 2015
    Inventors: Rahul Raman, Xiaoying Koh, Karthik Viswanathan, Ram Sasisekharan, Aarthi Chandrasekaran
  • Publication number: 20150147762
    Abstract: Pancreatic cancer can be detected using a monoclonal antibody which binds to pancreatic RNase 1 when a site in pancreatic RNase 1 capable of being modified with an N-glycan chain is not linked to a glycan chain, but which does not bind to pancreatic RNase 1 when an N-glycan chain is linked to the site. Also provided is a monoclonal antibody which can bind to pancreatic RNase 1 simultaneously with the binding of the aforementioned antibody to pancreatic RNase 1, and determining the ratio of A to B using the antibodies, wherein A represents the amount of the site located in the pancreatic RNase 1 capable of being modified with an N-glycan chain, wherein an N-glycan chain is linked or not linked to the site; and B represents the amount of the site located in the pancreatic RNase 1 capable of being modified with an N-glycan chain.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 28, 2015
    Applicant: TOSOH CORPORATION
    Inventor: Daisuke Nakatani
  • Publication number: 20150147763
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 28, 2015
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Publication number: 20150147334
    Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • Patent number: 9040669
    Abstract: Antigen binding proteins with T cell receptor-like paratopes, that is, with an antigen binding region specific for an human leukocyte antigen-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: May 26, 2015
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Nai-Kong Cheung, Dimiter Tassev, Jian Hu
  • Publication number: 20150141528
    Abstract: An in vitro diagnostic (IVD) device is used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole blood, plasma, serum, and/or cerebrospinal fluid (CSF). An IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format, either to a display device or to a storage device internal or external to the IVD.
    Type: Application
    Filed: June 2, 2014
    Publication date: May 21, 2015
    Applicant: BANYAN BIOMARKERS, INC.
    Inventor: Stephen Larner
  • Publication number: 20150141274
    Abstract: Disclosed herein are methods, compositions, and kits for isolating actively translated mRNA from heterogeneous cell populations. Also disclosed herein are methods, compositions, and kits for identifying cell types that respond to stimuli in heterogeneous cell populations.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 21, 2015
    Inventors: Jeffrey M. Friedman, Zachary A. Knight, Keith Tan, Kivan Birsoy
  • Publication number: 20150141347
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati
  • Publication number: 20150139980
    Abstract: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 21, 2015
    Inventors: Michael Tainsky, Madhumita Chatterjee, Gregory Dyson, Nancy Levin
  • Publication number: 20150140001
    Abstract: Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clecl4a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition for preventing or treating cancer comprising the antibody, a method for treating cancer by administering the antibody or the composition, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for diagnosing cancer using the composition, a composition for suppressing angiogenesis comprising a material for inhibiting expression of clecl4a, a kit for angiogenesis comprising the composition, a method for suppressing angiogenesis or treating cancer using the composition, and the use of the CTLD of clecl4a as an epitope for an antibody suppressive of angiogenesis.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 21, 2015
    Applicant: SCRIPPS KOREA ANTIBODY INSTITUTE
    Inventors: Suk Mook Lee, Min kyoung Ki, Mee Hyun Jeoung, Jong Rip Choi
  • Publication number: 20150141287
    Abstract: Genetic markers associated with intellectual disability as well as compositions, methods and kits for screening for genetic markers of intellectual disability, diagnosing intellectual disability and identifying individuals with a predisposition for offspring suffering from intellectual disability are provided.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 21, 2015
    Inventor: John B. Vincent
  • Publication number: 20150140000
    Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Inventors: Cécile Bonnafous, Laurent Gauthier, Yannis Morel, Carine Paturel, Ivan Perrot
  • Publication number: 20150143574
    Abstract: The invention relates to a new gene that is able to provide plants with resistance against pathogens, more preferably Verticillium, Ralstonia or Fusarium. Said gene is typical for Brassicaceae and encodes for a proteins having a sequence as depicted in FIG. 7 or FIG. 2A. Also provided are methods for enhancing the pathogen resistance of plants, wherein said plants preferably are Brassicaceae, but wherein the resistance also is functional in other plants. Further provided are host cells with a nucleotide construct encoding said protein.
    Type: Application
    Filed: May 24, 2013
    Publication date: May 21, 2015
    Inventors: Bart Pierre Hélène Joseph Thomma, Koste Abdissa Yadeta
  • Publication number: 20150140003
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 21, 2015
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • Publication number: 20150143584
    Abstract: This invention relates generally to nucleic acid sequences encoding proteins that are related to the presence of seed storage compounds in plants. More specifically, the present invention relates to Arabidopsis thaliana, Brassica napus, Glycine max and Oryza sativa nucleic acid sequences encoding sugar and lipid metabolism regulator proteins and the use of these sequences in transgenic plants. In particular, the invention is directed to methods fir manipulating sugar-related compounds and for increasing oil level and altering the fatty acid composition in plants and seeds. The invention further relates to methods of using these novel plant polypeptides to stimulate plant growth and/or to increase yield and/or composition of seed storage compounds.
    Type: Application
    Filed: November 19, 2014
    Publication date: May 21, 2015
    Applicant: BASF PLANT SCIENCE GMBH
    Inventors: Heiko A. Haertel, Garima Bhatt
  • Publication number: 20150139999
    Abstract: Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition. In particular the invention relates to antagonists of interferon proteins and associated methods of use as well as methods to develop neutralizing antibodies against IFN antagonists to treat viral infections.
    Type: Application
    Filed: June 5, 2014
    Publication date: May 21, 2015
    Inventors: Sergei V. Kotenko, Geoffrey L. Smith
  • Patent number: 9035029
    Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: May 19, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sanjaya Singh, Alisa K. Waterman, Erik Depla, Toon Laeremans, Diane Van Hoorick, Cedric Jozef Néotère Ververken
  • Patent number: 9034328
    Abstract: The present invention relates to an antibody or an antibody fragment thereof which recognizes an extracellular domain of erbB3 and inhibit EGF-like ligand-dependent phosphorylation of erbB3, a DNA encoding the antibody or the antibody fragment thereof, a method of producing the antibody or the antibody fragment thereof, a therapeutic drug including the antibody or the antibody fragment thereof, and therapeutic application using the antibody or the antibody fragment thereof.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: May 19, 2015
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventor: Nobuaki Takahashi
  • Publication number: 20150133637
    Abstract: The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 14, 2015
    Applicant: Ablynx N.V.
    Inventors: Welbeck Owusu Danquah, Friedrich Nolte, Catelijne Stortelers, Toon Laeremans
  • Publication number: 20150132277
    Abstract: Isolated monomeric aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 14, 2015
    Inventors: Paul Schimmel, Xiang-Lei Yang, Bonnie Slike
  • Publication number: 20150132311
    Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Inventors: Robert Arch, Jun Zhang, Michelle Madar, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning
  • Publication number: 20150132286
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.
    Type: Application
    Filed: September 18, 2014
    Publication date: May 14, 2015
    Inventors: Bruno DOMON, Ian MCCAFFREY, Vaibhav NARAYAN, Scott PATTERSON
  • Publication number: 20150132288
    Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: September 13, 2012
    Publication date: May 14, 2015
    Applicant: BiocerOX Products B.V.
    Inventors: Petrus Johannes Simons, Louis Boon
  • Publication number: 20150132224
    Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 14, 2015
    Inventors: Leon F. GARCIA-MARTINEZ, Ann Elisabeth CARVALHO JENSEN, Katie OLSON, Benjamin H. DUTZAR, Ethan W. OJALA, Brian R. KOVACEVICH, John A. LATHAM, Jeffrey T.L. SMITH
  • Publication number: 20150132303
    Abstract: A monoclonal antibody against oncostatin M specific receptor beta subunit, a hybridoma capable of producing the same and a medicament for treating atopic dermatitis comprising the same.
    Type: Application
    Filed: May 10, 2013
    Publication date: May 14, 2015
    Inventors: Yoshihiro Morikawa, Tadasuke Komori, Eiji Esashi, Ayumi Kotaki
  • Publication number: 20150132218
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Application
    Filed: October 20, 2014
    Publication date: May 14, 2015
    Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
  • Patent number: 9028830
    Abstract: The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: May 12, 2015
    Assignee: JN Biosciences, LLC
    Inventors: J. Yun Tso, Naoya Tsurushita, Nicholas F. Landolfi, Shankar Kumar
  • Patent number: 9029512
    Abstract: The present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: May 12, 2015
    Assignee: Nuclea Biotechnologies, Inc.
    Inventor: Patrick J. Muraca
  • Publication number: 20150125476
    Abstract: The present invention relates to an isolated immunogenic peptide chimera comprising a first peptide moiety comprising the amino acid sequence of SEQ ID NO: 1, or at least a contiguous 5 amino acid fragment thereof, a second peptide moiety comprising the amino acid sequence of SEQ ID NO: 2, or at least a contiguous 5 amino acid fragment thereof, and a linker joining the first and second peptide moieties, wherein the first peptide moiety is at the immunogenic peptide chimera's N-terminus and the second peptide moiety is at the immunogenic peptide chimera's C-terminus. Also disclosed is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 6, or at least a contiguous 5 amino acid fragment thereof, having a length sufficient to form ?-hairpin structure.
    Type: Application
    Filed: October 7, 2014
    Publication date: May 7, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventor: Timothy CARDOZO
  • Publication number: 20150126713
    Abstract: [Problem] An object of the present invention is to provide an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies, and means for using the antibody to prevent or treat various diseases such as ophthalmic disease, inflammatory bowel disease, or psoriasis in which human IL-23R is involved in pathogenesis. [Means for Solution] An anti-human IL-23R antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:10 or 14 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:6 or 18.
    Type: Application
    Filed: February 27, 2013
    Publication date: May 7, 2015
    Applicant: Astellas Pharma Inc.
    Inventors: Atsuo Yonezawa, Makoto Ohori, Takanori Sasaki, Hiromu Sato, Katsunari Taguchi